STUDY SEARCH RESULTS

2 studies found for your search request:  6482-012

A Study of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902)...
Condition: Carcinoma, Renal Cell
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT04736706
Status: Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902)...
Condition: Carcinoma, Renal Cell
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05899049
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site